SCHEMBL14877387

SCHEMBL14877387

O=c1[nH]c(-c2cccc3ccccc23)nc2ccc(N3CCOCC3)cc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 2/20 0.53
▸ FLT1 P17948 2/20 0.53
▸ KDR P35968 2/20 0.53
▸ PDGFRB P09619 1/20 0.53
▸ STAT3 P40763 1/20 0.53
▸ TDO2 P48775 1/20 0.53
▸ IDO2 Q6ZQW0 1/20 0.53
▸ APAF1 O14727 1/20 0.49
▸ CDC25B P30305 1/20 0.49
▸ CASP3 P42574 1/20 0.49
▸ SENP8 Q96LD8 1/20 0.49
▸ SENP7 Q9BQF6 1/20 0.49
▸ CBFB Q13951 1/20 0.47
▸ PRKDC P78527 2/20 0.47
▸ KDM4E B2RXH2 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ MAPT P10636 3/20 0.46
▸ HPGD P15428 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14877136 0.90 KDM4E (0.56) STAT3KDM4EALDH1A1MAPTHPGD
SCHEMBL14877439 0.89 KDM4E (0.55) STAT3KDM4EALDH1A1MAPTHPGD
SCHEMBL14877401 0.84 PDGFRB (0.57) FGFR1FLT1KDRPDGFRBSTAT3
SCHEMBL14877218 0.83 FGFR1 (0.50) FGFR1FLT1KDRPDGFRBSTAT3
SCHEMBL14877386 0.83 PRKDC (0.54) FGFR1FLT1KDRPDGFRBTDO2
SCHEMBL21666182 0.80 STAT3 (0.52) FGFR1FLT1KDRPDGFRBSTAT3
SCHEMBL18643544 0.77 STAT3 (0.61) FGFR1FLT1KDRPDGFRBSTAT3
SCHEMBL28135155 0.75 GUSB (0.69) KDM4EALDH1A1MAPTHPGDTNKS
SCHEMBL14883375 0.75 NPC1 (0.58) KDM4EALDH1A1MAPTHPGDTNKS
SCHEMBL30424336 0.75 FGFR1 (0.65) FGFR1FLT1KDRPDGFRBCBFB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045437-B2 2-aryl-4-quinazolinones and their pharmaceutical compositions CHINA MEDICAL UNIVERSITY (TW) 2015-06-02 — — US disclosed
US-9045437-B2 2-aryl-4-quinazolinones and their pharmaceutical compositions CHINA MEDICAL UNIVERSITY (TW) 2015-06-02 — — US disclosed
US-9045437-B2 2-aryl-4-quinazolinones and their pharmaceutical compositions CHINA MEDICAL UNIVERSITY (TW) 2015-06-02 — — US disclosed
US-9006239-B2 2-aryl-4-quinazolinones and their pharmaceutical compositions CHINA MEDICAL UNIVERSITY (TW) 2015-04-14 — — US disclosed
US-9006239-B2 2-aryl-4-quinazolinones and their pharmaceutical compositions CHINA MEDICAL UNIVERSITY (TW) 2015-04-14 — — US disclosed
US-9006239-B2 2-aryl-4-quinazolinones and their pharmaceutical compositions CHINA MEDICAL UNIVERSITY (TW) 2015-04-14 — — US disclosed
US-8710064-B2 2-aryl-4-quinazolinones and their pharmaceutical compositions CHINA MEDICAL UNIVERSITY (TW) 2014-04-29 — — US disclosed
US-20140018363-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CHINA MEDICAL UNIVERSITY (TW) 2014-01-16 — — US disclosed
US-20140018363-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CHINA MEDICAL UNIVERSITY (TW) 2014-01-16 — — US disclosed
US-20140018363-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CHINA MEDICAL UNIVERSITY (TW) 2014-01-16 — — US disclosed
US-20130310376-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CHINA MEDICAL UNIVERSITY (TW) 2013-11-21 — — US disclosed
US-20130310376-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CHINA MEDICAL UNIVERSITY (TW) 2013-11-21 — — US disclosed
US-20130102602-A1 2-Aryl-4-Quinazolinones And Their Pharmaceutical Compositions CHINA MEDICAL UNIVERSITY (TW) 2013-04-25 — — US disclosed
US-20130102602-A1 2-Aryl-4-Quinazolinones And Their Pharmaceutical Compositions CHINA MEDICAL UNIVERSITY (TW) 2013-04-25 — — US disclosed
US-20130102602-A1 2-Aryl-4-Quinazolinones And Their Pharmaceutical Compositions CHINA MEDICAL UNIVERSITY (TW) 2013-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102602-A1 2-Aryl-4-Quinazolinones And Their Pharmaceutical Compositions AQP4, KRAS, RB1 FGFR1 620/4885FLT1 1795/4885KDR 892/4885
US-20130310376-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CCNE2, NFE2, NR2E1 FGFR1 2322/4885FLT1 2533/4885KDR 631/4885
US-20140018363-A1 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS CCNE2, RB1, NR2E1 FGFR1 1767/4885FLT1 2199/4885KDR 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback